Assessment of Different Niosome Formulations for Optogenetic Applications: Morphological and Electrophysiological Effects
Authors:
- José David CeldránJCJosé David Celdrán
- Lawrence HumphreysLHLawrence Humphreys
- Desirée GonzálezDGDesirée González
- Cristina Soto-SánchezCSCristina Soto-Sánchez
- Gema Martínez-NavarreteGMGema Martínez-Navarrete
- Iván MaldonadoIMIván Maldonado
- Idoia GallegoIGIdoia Gallego
- Ilia Villate-BeitiaIlia Villate-Beitia
- Myriam Sainz-RamosMSMyriam Sainz-Ramos
- Gustavo PurasGPGustavo Puras
- José Luis PedrazJosé Luis Pedraz
- Eduardo FernándezEduardo Fernández
Open Access
- 1 July 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (7) , 1860
Abstract
Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.Keywords
Funding Information
- Spanish “Ministerio de Ciencia, Innovación y Universidades” (RTI2018-098969-B-I00, PRE2019-087693, DTS19/00175, PDC2022-133952-100, 899287)
- European Union’s Horizon 2020 Research and Innovation Programme (RTI2018-098969-B-I00, PRE2019-087693, DTS19/00175, PDC2022-133952-100, 899287)
This publication has 52 references indexed in Scilit:
- Mature neurons: equipped for survivalCell Death & Disease, 2013
- Ultra light-sensitive and fast neuronal activation with the Ca2+-permeable channelrhodopsin CatChNature Neuroscience, 2011
- Risk assessment in skin gene therapy: viral–cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectorsGene Therapy, 2011
- Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cellsGene Therapy, 2010
- New Approaches for the Study of Orexin FunctionJournal of Neuroendocrinology, 2010
- An optical neural interface:in vivocontrol of rodent motor cortex with integrated fiberoptic and optogenetic technologyJournal of Neural Engineering, 2007
- Cationic liposomes as non‐viral carriers of gene medicines: Resolved issues, open questions, and future promisesMedicinal Research Reviews, 2006
- Millisecond-timescale, genetically targeted optical control of neural activityNature Neuroscience, 2005
- Low toxicity of cationic lipid-based emulsion for gene transferBiomaterials, 2004
- Gene Therapy for Human Genetic Disease?Science, 1972